19.10.19: Start of Quiet Period
Start of Quiet PeriodLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 16, 2019 Category: Pharmaceuticals Source Type: news
30.10.19: Q3 2019 News Conference Call
Q3 2019 News Conference CallLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 16, 2019 Category: Pharmaceuticals Source Type: news
30.10.19: Q3 2019 Investor Conference Call
Q3 2019 Investor Conference CallLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 16, 2019 Category: Pharmaceuticals Source Type: news
07.11.19: Morningstar Management Behind the Moat Conference, Chicago, U.S.A.
Morningstar Management Behind the Moat Conference, Chicago, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 15, 2019 Category: Pharmaceuticals Source Type: news
21.11.19: CACIB's 8th Annual Industrial, Infrastructure and Utilities Credit Seminar, London, UK
CACIB's 8th Annual Industrial, Infrastructure and Utilities Credit Seminar, London, UKLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 15, 2019 Category: Pharmaceuticals Source Type: news
13.11.19: Morgan Stanley Global Chemical and Agriculture Conference, Boston, U.S.A.
Morgan Stanley Global Chemical and Agriculture Conference, Boston, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 14, 2019 Category: Pharmaceuticals Source Type: news
18.11.19: DZ Bank Germany Conference, Frankfurt, Germany
DZ Bank Germany Conference, Frankfurt, GermanyLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 14, 2019 Category: Pharmaceuticals Source Type: news
25.11.19: UBS German Senior Investor Day, Munich, Germany
UBS German Senior Investor Day, Munich, GermanyLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 14, 2019 Category: Pharmaceuticals Source Type: news
26.11.19: Redburn CEO Conference, London, UK
Redburn CEO Conference, London, UKLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 14, 2019 Category: Pharmaceuticals Source Type: news
14.10.19: Not intended for U.S. and UK Media
U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill medical patientsA new oral option for patients in the U.S. with acute medical illnesses at risk for thromboembolic complications who are not at high risk of bleeding / Rivaroxaban is the only non vitamin K antagonist oral anticoagulant (NOAC) approved in the U.S for the continuum of venous thromboembolism (VTE) care, from prevention and treatment of initial VTE through extended prevention of recurrent VTEmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 14, 2019 Category: Pharmaceuticals Source Type: news
01.10.19: Ertharin Cousin to become member of Bayer AG Supervisory Board
Ertharin Cousin to become member of Bayer AG Supervisory BoardInternational expert in the area of nutrition and agriculture / Cousin succeeds Thomas Ebeling, who stepped down at the end of Septembermehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 1, 2019 Category: Pharmaceuticals Source Type: news
28.09.19: Not intended for U.S. and UK Media - European Society for Medical Oncology (ESMO) Congress 2019
Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer79% overall response rate (ORR) in 153 evaluable adult and pediatric patients at time of new data cut off (February 19, 2019); results consistent with previous publications(1,2) / Similar ORR of 75% in patients with brain metastases(1), adding to the previously reported evidence for larotrectinib's activity in central nervous system (CNS) / Median progression free survival (mPFS) of 28.3 months and median overall survival (mOS) of more than three years (44.4 months) was achieved...
Source: Bayer IR Newsfeed: Events - September 28, 2019 Category: Pharmaceuticals Source Type: news
23.09.19: Not intended for U.S. and UK Media
Vitrakvi® (larotrectinib) receives first tumor-agnostic approval in EUPrecision oncology treatment Vitrakvi® (larotrectinib) approved for the treatment of adults and children with locally advanced or metastatic solid tumors that have a rare genomic alteration called an NTRK gene fusion / Vitrakvi, which was exclusively designed to treat TRK fusion cancer, is the first therapy in the EU with a tumor-agnostic indication / Larotrectinib provides high response rates and durable responses in adults and children with TRK fusion cancer, including primary CNS tumors and brain metastases / In studies, larotrectinib demonstrated a...
Source: Bayer IR Newsfeed: Events - September 23, 2019 Category: Pharmaceuticals Source Type: news
20.09.19: Not intended for U.S. and UK Media - European Society for Medical Oncology (ESMO) Congress 2019
Bayer data at ESMO 2019 highlights innovation in cancer researchNew data for larotrectinib on durability of response in patients with TRK fusion cancer to be presented in a poster discussion on September 28 / Data from Bayer's prostate cancer franchise to be presented, including clinical relevance of drug-drug interactions in men with nmCRPC taking darolutamide and real-world data and pain evalutation data in men with mCRPC treated with radium-223 dichloride / New analyses from the Phase II study REGOBONE evaluating the efficacy and safety of regorafenib in patients with rare locally advanced or metastatic relapsed chondro...
Source: Bayer IR Newsfeed: Events - September 20, 2019 Category: Pharmaceuticals Source Type: news
10.09.19: Changes to Board of Management structure as of January 1, 2020:
Bayer reduces size of Board of Management from seven to five membersmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 10, 2019 Category: Pharmaceuticals Source Type: news
